目的探讨蛋白酪氨酸激酶抑制剂抗肿瘤作用机理及其研究进展。
Objective To approach the mechanism of action of anticancer and the investigation progress of protein tyrosine kinase (PTK).
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
因此，本研究的目的是调查金雀异黄素，一种蛋白质酪氨酸激酶抑制剂，对有急性或慢性糖尿病炎症小鼠（诱导脲佐菌素）的影响。
Therefore, the aim of this study is to investigate the effects of genistein, a protein tyrosine kinase inhibitor, on acute and chronic inflammation in diabetic mice (induced by streptozotocin).
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内，以her2为靶点的抗肿瘤治疗研究成为热点，并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
包括单克隆抗体、酪氨酸激酶抑制剂、融合蛋白、瘤苗在内，以her2为靶点的抗肿瘤治疗研究成为热点，并显示出广阔的应用前景。
Anticancer therapies targeting HER2 have shown promise and become a focus, including monoclonal antibody, tyrosine kinases inhibitor, tumor vaccine, fusion protein.
应用推荐